Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

15.16 +0.92 (+6.46%)
Streaming Delayed Price Updated: 3:23 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
The Latest Analyst Ratings for MiNK Therapeutics
 
Via Benzinga
Recap: MiNK Therapeutics Q1 Earnings
 
Via Benzinga
Preview: MiNK Therapeutics's Earnings
 
Via Benzinga
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
Sacks Parente Golf And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by more than 300 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
From MiNK Therapeutics
Via GlobeNewswire
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
From MiNK Therapeutics
Via GlobeNewswire
Over $1M Bet On This Basic Materials Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny... 
Via Benzinga
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
First Foundation And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.